CoChat
Sign Up
Cited by 177Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatmentsNuclear Receptors and Signaling

APOE genotype regulates pathology and disease progression in synucleinopathy

Open access
Davis, Albert A., Inman, Casey E., Wargel, Zachary M., Dube, Umber, Freeberg, Brittany M., Galluppi, Alexander, Haines, Jessica N., Dhavale, Dhruva D. +9 more·2020·Science Translational Medicine
DOI 10.1126/scitranslmed.aay3069PMC PMC7289511
Open this paper in CoChat — free account

Abstract

APOE genotype regulates disease development in mouse models of α-synucleinopathy and affects cognition in patients with Parkinson’s disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aay3069

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • APOEε4 has been associated with a faster rate of cognitive decline in people with Parkinson disease, independent of Alzheimer disease neuropathology assessed by levels of CSF biomarkers Aβ42 and pTau.

    “APOEε4 has been associated with a faster rate of cognitive decline in people with Parkinson disease, independent of AD neuropathology assessed by levels of CSF biomarkers Aβ42 and pTau69.”

    From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [69]

  • The APOE2 mice have improved motor function and prolonged survival compared with APOE3-expressing mice, suggesting that the effect of APOE on α-synucleinopathies is independent of its effect on Aβ.

    “Furthermore, the APOE2 mice have improved motor function and prolonged survival compared with APOE3-expressing mice, suggesting that the effect of APOE on α-synucleinopathies is independent of its effect on Aβ69.”

    From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [69]

  • Studies using APOE-targeted replacement mice crossed with mutant α-synuclein mice have reported that APOE4 mice have increased aggregation of α-synuclein, whereas APOE2 mice have very limited α-synuclein aggregates.

    “Studies using APOE-targeted replacement (APOE-TR) mice crossed with mutant α-synuclein (αSyn) mice have reported that APOE4 mice have increased aggregation of αSyn, whereas APOE2 mice have very limited αSyn aggregates.”

    From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [69]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 63

  1. [2]Willis AW, Predictors of survival in patients with Parkinson disease. Archives of neurology 69, 601– 607 (2012). 22213411 PMC3599783
  2. [3]Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG, The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Movement disorders: official journal of the Movement Disorder Society 23, 837– 844 (2008). 18307261
  3. [4]McKeith IG, Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89, 88– 100 (2017). 28592453 PMC5496518
  4. [5]Bras J, Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human molecular genetics, (2014). PMC4222357 24973356
  5. [6]Guerreiro R, Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet neurology 17, 64– 74 (2018). 29263008 PMC5805394
  6. [7]Mata IF, APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA neurology 71, 1405– 1412 (2014). 25178429 PMC4227942
  7. [8]Morley JF, Genetic influences on cognitive decline in Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society 27, 512– 518 (2012). 22344634 PMC3323737
  8. [9]Braak H, Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of aging 24, 197– 211 (2003). 12498954
  9. [10]Halliday G, Hely M, Reid W, Morris J, The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta neuropathologica 115, 409– 415 (2008). 18231798
  10. [11]Irwin DJ, Lee VM, Trojanowski JQ, Parkinson’s disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nature reviews. Neuroscience 14, 626– 636 (2013). 23900411 PMC4017235
  11. [12]Kotzbauer PT, Pathologic accumulation of alpha-synuclein and Abeta in Parkinson disease patients with dementia. Archives of neurology 69, 1326– 1331 (2012). 22825369 PMC3616136
  12. [14]Holtzman DM, Herz J, Bu G, Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harbor perspectives in medicine 2, a006312 (2012). 22393530 PMC3282491
  13. [15]Irwin DJ, Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet neurology 16, 55– 65 (2017). 27979356 PMC5181646
  14. [16]Tsuang D, APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA neurology 70, 223– 228 (2013). 23407718 PMC3580799
  15. [17]Dickson DW, APOE epsilon4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology 91, e1182– e1195 (2018). 30143564 PMC6161556
  16. [18]Sabir MS, Assessment of APOE in atypical parkinsonism syndromes. Neurobiology of disease 127, 142– 146 (2019). 30798004 PMC6588472
  17. [19]Lee MK, Human alpha-synuclein-harboring familial Parkinson’s disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 99, 8968– 8973 (2002). 12084935 PMC124407
  18. [22]Luk KC, Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (New York, N.Y.) 338, 949– 953 (2012). PMC3552321 23161999
  19. [23]Federoff M, Jimenez-Rolando B, Nalls MA, Singleton AB, A large study reveals no association between APOE and Parkinson’s disease. Neurobiology of disease 46, 389– 392 (2012). 22349451 PMC3323723
  20. [24]Paul KC, APOE, MAPT, and COMT and Parkinson’s Disease Susceptibility and Cognitive Symptom Progression. Journal of Parkinson’s disease, (2016). PMC5927361 27061069
  21. [25]Tropea TF, APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society 33, 289– 297 (2018). 29168904 PMC5809205
  22. [26]Shahid M, An increased rate of longitudinal cognitive decline is observed in Parkinson’s disease patients with low CSF Ass42 and an APOE epsilon4 allele. Neurobiology of disease 127, 278– 286 (2019). 30826425 PMC6588475
  23. [27]Marek K. e. a., for the Parkinson’s Progression Markers Initiative, The Parkinson Progression Marker Initiative (PPMI). Progress in neurobiology 95, 629– 635 (2011). 21930184 PMC9014725
  24. [28]Eusebi P, Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson’s disease: A systematic review and meta-analysis. Movement disorders: official journal of the Movement Disorder Society 32, 1389– 1400 (2017). 28880418
  25. [29]Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA, Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64, 1404– 1410 (2005). 15851731
  26. [30]Galvin JE, Pollack J, Morris JC, Clinical phenotype of Parkinson disease dementia. Neurology 67, 1605– 1611 (2006). 17101891
  27. [31]Hurtig HI, Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 54, 1916– 1921 (2000). 10822429
  28. [32]Parnetti L, Cerebrospinal fluid biomarkers in Parkinson’s disease with dementia and dementia with Lewy bodies. Biological psychiatry 64, 850– 855 (2008). 18395699
  29. [33]Jellinger KA, A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochimica et biophysica acta 1792, 730– 740 (2009). 18718530
  30. [34]Irwin DJ, Neuropathologic substrates of Parkinson disease dementia. Annals of neurology 72, 587– 598 (2012). 23037886 PMC3484250
  31. [35]Gao L, Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson’s disease diagnosis: a systematic review and meta-analysis. The International journal of neuroscience 125, 645– 654 (2015). 25202803
  32. [37]Davidson WS, Jonas A, Clayton DF, George JM, Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. The Journal of biological chemistry 273, 9443– 9449 (1998). 9545270
  33. [38]George JM, Jin H, Woods WS, Clayton DF, Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361– 372 (1995). 7646890
  34. [39]Emamzadeh FN, Aojula H, McHugh P, Allsop D, Effects of different isoforms of apoE on aggregation of the alpha-synuclein protein implicated in Parkinson’s disease. Neuroscience letters, (2016). 26921451
  35. [40]Rohn TT, Mack JM, Apolipoprotein E Fragmentation within Lewy Bodies of the Human Parkinson’s Disease Brain. International journal of neurodegenerative disorders 1, (2018). PMC6159338 30272057
  36. [41]Wilhelmus MM, Apolipoprotein E and LRP1 Increase Early in Parkinson’s Disease Pathogenesis. The American journal of pathology 179, 2152– 2156 (2011). 21907175 PMC3204035
  37. [42]Fantini J, Yahi N, The driving force of alpha-synuclein insertion and amyloid channel formation in the plasma membrane of neural cells: key role of ganglioside- and cholesterol-binding domains. Advances in experimental medicine and biology 991, 15– 26 (2013). 23775688
  38. [43]Danzer KM, Exosomal cell-to-cell transmission of alpha synuclein oligomers. Molecular neurodegeneration 7, 42 (2012). 22920859 PMC3483256
  39. [44]Danzer KM, Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 25, 326– 336 (2011). 20876215 PMC3005424
  40. [45]Emmanouilidou E, Assessment of alpha-synuclein secretion in mouse and human brain parenchyma. PloS one 6, e22225 (2011). 21779395 PMC3136497
  41. [48]Ulrich JD, ApoE facilitates the microglial response to amyloid plaque pathology. The Journal of experimental medicine 215, 1047– 1058 (2018). 29483128 PMC5881464
  42. [50]Shi Y, Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. The Journal of experimental medicine 216, 2546– 2561 (2019). 31601677 PMC6829593
  43. [52]Peng C, Cellular milieu imparts distinct pathological alpha-synuclein strains in alpha-synucleinopathies. Nature 557, 558– 563 (2018). 29743672 PMC5970994
  44. [53]Cairns NJ, Apolipoprotein E e4 allele frequency in patients with multiple system atrophy. Neuroscience letters 221, 161– 164 (1997). 9121689
  45. [54]Ogaki K, Multiple system atrophy and apolipoprotein E. Movement disorders: official journal of the Movement Disorder Society 33, 647– 650 (2018). 29442376 PMC5889322
  46. [55]Uemura N, Slow Progressive Accumulation of Oligodendroglial Alpha-Synuclein (alpha-Syn) Pathology in Synthetic alpha-Syn Fibril-Induced Mouse Models of Synucleinopathy. Journal of neuropathology and experimental neurology 78, 877– 890 (2019). 31504665 PMC6934438
  47. [56]Ibanez L, Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease. Frontiers in neuroscience 12, 230 (2018). 29692703 PMC5902712
  48. [57]Parsian A, Racette B, Goldsmith LJ, Perlmutter JS, Parkinson’s disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics 79, 458– 461 (2002). 11863377
  49. [58]Liu C, CSF tau and tau/Abeta42 predict cognitive decline in Parkinson’s disease. Parkinsonism & related disorders 21, 271– 276 (2015). 25596881 PMC4603566
  50. [59]Hall S, CSF biomarkers and clinical progression of Parkinson disease. Neurology 84, 57– 63 (2015). 25411441 PMC4336091
  51. [60]Backstrom DC, Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. JAMA neurology 72, 1175– 1182 (2015). 26258692
  52. [61]Siderowf A, CSF amyloid {beta} 1–42 predicts cognitive decline in Parkinson disease. Neurology 75, 1055– 1061 (2010). 20720189 PMC2942062
  53. [62]Montine TJ, CSF Abeta(42) and tau in Parkinson’s disease with cognitive impairment. Movement disorders: official journal of the Movement Disorder Society 25, 2682– 2685 (2010). 20818673 PMC2978754
  54. [63]Kim S, Transneuronal Propagation of Pathologic alpha-Synuclein from the Gut to the Brain Models Parkinson’s Disease. Neuron, (2019). PMC6706297 31255487
  55. [64]Holtzman DM, Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America 97, 2892– 2897 (2000). 10694577 PMC16026
  56. [68]Langfelder P, Horvath S, WGCNA: an R package for weighted correlation network analysis. BMC bioinformatics 9, 559 (2008). 19114008 PMC2631488
  57. [69]The Gene Ontology Resource: 20 years and still GOing strong. Nucleic acids research 47, D330– d338 (2019). 30395331 PMC6323945
  58. [70]Ashburner M, Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nature genetics 25, 25– 29 (2000). 10802651 PMC3037419
  59. [71]Mi H, PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. Nucleic acids research 45, D183– d189 (2017). 27899595 PMC5210595
  60. [72]Volpicelli-Daley LA, Luk KC, Lee VM, Addition of exogenous alpha-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous alpha-synuclein to Lewy body and Lewy neurite-like aggregates. Nature protocols 9, 2135– 2146 (2014). 25122523 PMC4372899
  61. [73]Hughes AJ, Daniel SE, Kilford L, Lees AJ, Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. Journal of neurology, neurosurgery, and psychiatry 55, 181– 184 (1992). PMC1014720 1564476
  62. [74]Racette BA, Rundle M, Parsian A, Perlmutter JS, Evaluation of a screening questionnaire for genetic studies of Parkinson’s disease. American journal of medical genetics 88, 539– 543 (1999). 10490713
  63. [75]Factor SA, Postural instability/gait disturbance in Parkinson’s disease has distinct subtypes: an exploratory analysis. Journal of neurology, neurosurgery, and psychiatry 82, 564– 568 (2011). PMC4646086 20884673

Cited by

Sorted by citations

Authors
Davis, A. A., Inman, C. E., Wargel, Z. M., Dube, U., Freeberg, B. M., Galluppi, A., Haines, J. N., Dhavale, D. D., Miller, R., Choudhury, F. A., Sullivan, P. M., Cruchaga, C., Perlmutter, J. S., Ulrich, J. D., Benitez, B. A., Kotzbauer, P. T., & Holtzman, D. M.
Affiliations
  • Washington University in St. Louis (US)
  • Duke Medical Center (US)
  • Hope Center for Neurologic Disease, Washington University, St. Louis, MO 63110, USA.
Corresponding author
  • Davis, Albert A.
  • Holtzman, David M.
ORCID
Venue
Science Translational Medicine
Publisher
American Association for the Advancement of Science (AAAS)
Published
2020-02-05
Volume
12
Issue
529
Pages
eaay3069
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
DOI
10.1126/scitranslmed.aay3069
PMC
PMC7289511
OpenAlex
W3004888206
Cited by
177
References
12
Citations by year
2026: 19 · 2025: 33 · 2024: 29 · 2023: 24 · 2022: 31 · 2021: 23 · 2020: 18
FWCI
10.33
Type
journal article
Language
en
Open access
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • HAL (submittedVersion)
Funders
  • National Institutes of Health (K08NS101118, R01AG044546, RF1AG053303, RF1AG058501, U01AG052411, U01AG058922, NS097799, R01NS090934, R01AG047644, NS075321)
  • the JPB Foundation
  • American Brain Foundation
  • American Academy of Neurology
  • BrightFocus Foundation
  • Mary E. Groff Surgical and Medical Research and Education Charitable Trust
  • Dobbins Family Fund
  • Barnes-Jewish Hospital Foundation
  • The Riney Foundation
  • The American Parkinson Disease Association
  • The Greater St. Louis Chapter of the APDA
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
Keywords
APOE genotype, synucleinopathies, Parkinson's disease, mouse model, disease progression, cognitive function, neurodegeneration
MeSH terms
Synucleinopathies, Animals, Apolipoproteins E, Genotype, Humans, Disease Progression, Mice, Apolipoprotein E4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review